ProCE Banner Activity

Clinical Management of Pruritus in PBC

Podcast Episodes

Although there is currently no FDA-approved treatment for pruritus in primary biliary cholangitis (PBC), symptoms can be mitigated with nonpharmacologic or pharmacologic agents. In this podcast, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, discuss the clinical management of pruritus in PBC and associated challenges.

Released: December 18, 2024

Expiration: December 17, 2025

Share

Faculty

Stuart C. Gordon

Stuart C. Gordon, MD

Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan

Marlyn J. Mayo

Marlyn J. Mayo, MD

Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas

Pam Rivard

Pam Rivard, RN

Person Living With PBC

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline

Disclosure

Primary Author

Stuart C. Gordon, MD

Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan

Stuart C. Gordon, MD: researcher: AbbVie, Arbutus, COUR Pharmaceuticals, CymaBay, GlaxoSmithKline, Ipsen, Mirum Pharmaceuticals; advisor: CymaBay, GlaxoSmithKline, Ipsen.

Marlyn J. Mayo, MD

Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas

Marlyn J. Mayo, MD: consultant/advisor/speaker: CymaBay, GlaxoSmithKline, Intercept, Intra-Sana, Ipsen; researcher: CymaBay, GlaxoSmithKline, Intercept, Ipsen, Mirum.

Pam Rivard, RN

Person Living With PBC

Pam Rivard, RN, has no relevant financial relationships to disclose.